Bayer has added another phase 3 trial into its registration programme for oral Factor XIa inhibitor asundexian, signalling growing confidence in a drug that generated mixed results in phase 2.

The Philippine Energy Regulatory Commission’s (ERC) value to the Filipino people has been inestimable, guiding the nation’s electricity landscape toward competition, affordability, and sustainability, ...